Advertisement

Advertisement
Immunotherapy
Gynecologic Cancers

KEYNOTE-158: Pembrolizumab in Previously Treated Advanced Cervical Cancer

As reported in the Journal of Clinical Oncology by Chung et al, the phase II KEYNOTE-158 trial showed activity of pembrolizumab in previously treated...

Prostate Cancer

Enzalutamide Plus ADT Extends Progression-Free Survival in Metastatic Hormone-Sensitive Prostate Cancer

Adding enzalutamide to androgen-deprivation therapy (ADT) significantly prolonged radiographic progression-free survival in men with metastatic hormone-sensitive...

Breast Cancer

Addition of Radiotherapy After Breast-Conserving Surgery Based on Level of Tumor-Infiltrating Lymphocytes

In a long-term follow-up of the Swedish Breast Cancer Group 91 Radiotherapy trial reported in the Journal of Clinical Oncology, Kovács et al...


Advertisement
Immunotherapy

The Future of Immunotherapy: Building on Checkpoint Blockade

The emergence of anticancer agents that block immune checkpoints has transformed the field of oncology, leading to durable responses and improvements in overall survival...

Lymphoma
Genomics/Genetics

Addition of Bortezomib to R-CHOP in DLBCL Subtypes Identified With Gene-Expression Profiling

In the phase III REMoDL-B trial reported in The Lancet Oncology, Davies et al found that the addition of bortezomib to standard R-CHOP...

Advertisement




More Top Stories

Prostate Cancer

Howard I. Scher, MD, on Prostate Cancer: Circulating Tumor Cells as a Surrogate Endpoint for Survival

Immunotherapy

Anti–TIM-3 Antibody Well Tolerated as Monotherapy and in Combination With Anti–PD-L1 Antibody

INITIAL DATA from the ongoing, multicenter, first-in-human, phase Ia/Ib dose-escalation and -expansion study suggest that an anti–T-cell immunoglobulin domain and mucin domain–containing molecule 3 (anti–TIM-3) antibody alone or in combination with immune checkpoint blockade could counter intrinsic ...

Advertisement

Study Finds Medicaid Reimbursement for Radiation Therapy Varies Widely State-to-State

A new study found wide state-to-state variations in Medicaid reimbursements to physicians who treat patients with cancer with radiation therapies. These differences could compound existing disparities in access to health care in rural communities, which tend to have higher Medicaid...

Bladder Cancer
Immunotherapy

Nicholas Vogelzang, MD, on Urothelial Cancer: Results From a Trial on Lenvatinib Plus Pembrolizumab

Immunotherapy

The Future of Immunotherapy: Building on Checkpoint Blockade

THE EMERGENCE of anticancer agents that block immune checkpoints has transformed the field of oncology, leading to durable responses and improvements in overall survival in melanoma, renal cell carcinoma, head/neck squamous cell carcinoma, urothelial bladder cancer, and non–small cell lung cancer....

Hematologic Malignancies
Multiple Myeloma

FDA Warning: Investigational Use of Venetoclax in Multiple Myeloma

On March 21, 2019, the U.S. Food and Drug Administration (FDA) posted a safety statement on the investigational use of venetoclax in multiple myeloma. The statement alerts health-care professionals and patients about the suspension of the BELLINI trial (ClinicalTrials.gov identifier NCT02755597)...

Complementary and Alternative Medicine Use in Patients With Cancer

In a recent study focusing on patients with cancer and cancer survivors, one-third of patient participants reported use of complementary and alternative medicines such as meditation, yoga, acupuncture, herbal medicine, and supplements. These findings were published by Sanford et al in JAMA...

Lung Cancer
Neuroendocrine Tumors

Aaron S. Mansfield, MD, on Treating Rare Thoracic Cancers: Status Update

Immunotherapy
Pancreatic Cancer

VISTA Checkpoint Implicated in Pancreatic Cancer Immunotherapy Resistance

Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers. A research team from The University of Texas MD Anderson Cancer Center...

Advertisement

KEYNOTE-158: Pembrolizumab in Previously Treated Advanced Cervical Cancer

As reported in the Journal of Clinical Oncology by Chung et al, the phase II KEYNOTE-158 trial showed activity of pembrolizumab in previously treated programmed cell death ligand 1 (PD-L1)-positive advanced cervical cancer. The study supported the 2018 accelerated approval of pembrolizumab in this...